Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI).

Abstract

VEXAS syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS-specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease activity over time, thereby supporting clinical research and informing patient care in this emerging disease. This study aimed to develop a comprehensive DAI to assess disease-related inflammation across affected organ systems in patients with VEXAS syndrome. Inflammatory manifestations of VEXAS were previously identified through a systematic literature review and expert input. A multinational expert advisory committee developed the VEXAS-DAI using modified Delphi methodology until consensus (defined as ≥75% concurrence) was reached. Item grading was adapted from the Common Terminology Criteria for Adverse Events (CTCAE) criteria. Scoring criteria were developed based on 158 test cases using the Physician Global Assessment of Inflammation. Consensus on the VEXAS-DAI was achieved after four Delphi rounds. The index assesses inflammatory activity at the time of evaluation across 12 domains: inflammatory rash, chondritis, periorbital, ophthalmologic, joint, pulmonary, cardiovascular, genitourinary, neurological, oral and gastrointestinal, renal, and constitutional symptoms. The total score ranges from 0 to 40. The VEXAS-DAI is a novel instrument designed to quantify active inflammation over time in patients with VEXAS syndrome. Prospective validation within a clinical trial setting is ongoing.